Your session is about to expire
← Back to Search
Procedure
Silver-Based Dressing for LVAD Infection (LVAD-SilverD Trial)
N/A
Recruiting
Led By Liviu Klein, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Summary
This trial is testing a new bandage with a silver patch to prevent infections and skin problems. The silver helps kill germs, aiming to keep the area clean. Silver has been used in wound care to reduce bacteria and promote healing since 1968.
Who is the study for?
This trial is for adults over 18 who have had a Left Ventricular Assist Device (LVAD) implanted as either destination therapy or bridge to transplant at the Academic Medical Center within the specified dates. It's not for those with previous device infections or sternal wound infections.
What is being tested?
The study tests a new driveline dressing protocol using Silverlon, a silver-based barrier, aimed at reducing infection and skin issues in LVAD patients. This pilot RCT will evaluate infection rates, skin reactions, comfort, ease of use, adherence to the protocol and cost-effectiveness.
What are the potential side effects?
Potential side effects may include skin irritation or allergic reactions due to the silver in Silverlon dressings. However, part of this study's purpose is to assess if these dressings actually decrease such dermatitis incidents.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Driveline infection
Secondary outcome measures
Allergies
Comfort
Speciation
Side effects data
From 2022 Phase 1 trial • 31 Patients • NCT042387283%
open area in inframammary fold
100%
80%
60%
40%
20%
0%
Study treatment Arm
Silverlon Arm
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: SilverDExperimental Treatment1 Intervention
The SIlverD arm includes:
For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly.
For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly.
Group II: ControlDActive Control1 Intervention
The ControlD arm includes:
For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours.
For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Silverlon
2020
Completed Phase 1
~160
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Left Ventricular Assist Device (LVAD) infections, such as silver-based dressing barriers, utilize antimicrobial properties to reduce infection rates. Silver ions released from these dressings disrupt bacterial cell membranes, interfere with enzyme function, and inhibit DNA replication, thereby reducing bacterial colonization and infection.
This is particularly important for LVAD patients as it helps prevent severe complications like sepsis and device failure, ultimately improving patient outcomes and the longevity of the device.
Oxacillin plus ertapenem rapidly clears persistent left ventricular assist device-related methicillin-susceptible Staphylococcus aureus bacteremia.Secondary prevention of coronary artery disease with antimicrobials: current status and future directions.
Oxacillin plus ertapenem rapidly clears persistent left ventricular assist device-related methicillin-susceptible Staphylococcus aureus bacteremia.Secondary prevention of coronary artery disease with antimicrobials: current status and future directions.
Find a Location
Who is running the clinical trial?
International Consortium of Circulatory Assist CliniciansOTHER
1 Previous Clinical Trials
150 Total Patients Enrolled
University of California, San FranciscoLead Sponsor
2,528 Previous Clinical Trials
15,242,612 Total Patients Enrolled
Liviu Klein, MDPrincipal InvestigatorUniversity of California, San Francisco
4 Previous Clinical Trials
694 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have received donor lymphocyte infusion (DLI) in the past.You have had an infection in the chest area where the breastbone is located in the past.You have had a previous surgery to replace a heart device due to an infection.
Research Study Groups:
This trial has the following groups:- Group 1: SilverD
- Group 2: ControlD
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger